Penelope Kokkinides is the Chief Administrative officer of InnovaCare Health, whom has been involved with the company for many years before re-joining in 2015. Before, she has held other roles in clinical operations and as the Chief Operating Officer. Her passion is for developing programs and managing care to ensure that the organization is as efficient as possible.She has held a multitude of other roles throughout her career: strategy and management for managed care were a big portion of her career. She briefly left Innovacare to take on roles at UnitedHealthCare and Touchstone Health. Her goal was to develop the company’s health and implementing a health/managed care model.
Her days don’t look the same: each day keeps her on her toes and she travels constantly. She has a great team of people whom she surrounds herself with in order to develop ideas. The team she is a part of allows her to have full synergy with in order to become her best alongside with her team. Furthermore, she is constantly thinking forward about what needs to be done on the next day. She has also had a very rewarding career which has spanned a multitude of different positions. She is very organized and focused on what needs to be done for success.InnovaCare Health is a company which provides managed healthcare services to their customers in North America. They offer high quality Medicare/Medicare Advantage plans that are sustainable and cost-effective. The company aims to redefine healthcare and offer a coordinated model of healthcare in Puerto Rico.
A coordinated approach has served InnovaCare Health’s patients well to ensure that their needs are met. The company prides itself on patient-centered leadership and on ensuring that the patient care models are sustainable.The company is designed to provide the executive leadership required to provide innovative care to patients across the country. This comes through decades of experience, as well as an emphasis on priority of the needs of patients. Members are served by a huge network of primary care providers. This network is designed to ensure that the patients’ needs are met effectively within the Puerto Rican government’s health plan. Their mission is to provide broad health coverage through a coordinated care model. This is combined with the leadership of a highly experienced executive team whom have decades of experience.
Jim Tananbaum is the CEO of Foresite Capital, a venture capital company that supports entrepreneurs and startups with innovative ideas that address the unmet healthcare needs. In a recent interview, Jim said that his 25 years’ experience gave him an insight into the factors that are essential to the success of entrepreneurs and business in the industry. He notes that most nascent entrepreneurs neither understand nor have what it takes to succeed. Foresite Capital fills the gap by providing capital, information and networks to help them succeed.
To determine a viable investment, Jim Tananbaum and his colleagues take the time to find out the greatest need in that sector. To achieve this requires a lot of reading and analysis of the current trends. But he points out that learning is the only way to find the best solutions. Foresite has invested in companies offering services in biopharmaceuticals, diagnostic and genomic sequencing and medical services. Jim points out that their duty is to provide means by which these businesses can make impactful innovations in healthcare.
Protagonist Therapeutics, Intarcia, 10X Genomics and Aimmune Therapeutics are the company’s outstanding investments. Protagonist Therapeutics uses peptides to develop a treatment for irritable bowel disease. Intarcia is creating an implanted pump, ITCA 650, for treating diabetes. 10X Genomics is developing genetic sequencing technology while Aimmune works to desensitize allergic patients. Foresite Capital invested more than $450 million in 2015 in these products.
The leadership of Jim Tananbaum in the healthcare industry spans over 25 years creating many profitable companies. He first co-founded GelTex Pharmaceuticals. The company developed two drugs and raised $1.6 billion from their sale. One of the drugs, Renagel, earned nearly $200 million per year. Theravance Inc. is another successful company he co-founded. His accomplishment in healthcare investment ranks him #52 among the leading investors in technology.
The healthcare investment genus has a strong educational background in technical skills from the world’s most prestigious universities. Jim Tananbaum attended Yale University for his bachelor of science in electrical engineering from Yale University and obtained his M.S from Massachusetts Institute of Technology. He also studied at Harvard for his M.D and M.B.A.
Click here: https://www.linkedin.com/in/jim-tananbaum-a7562a7/